GT Medical Technologies, Inc.

GT has developed an innovative approach to the treatment of brain tumors by combining a conformable collagen matrix with brachytherapy (radiation) seeds. The company’s first therapy, GammaTile™, was recently cleared by the FDA for use in the treatment of recurrent intracranial neoplasms and GT plans to launch the product in Q4 of 2018.  The product has the promise to revolutionize treatment for 175,000 patients/year in the US alone.